Anebulo Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

License Agreement (Details Narrative) - USD ($)		1 Months Ended		2 Months Ended	3 Months Ended		9 Months Ended
License Agreement (Details Narrative) - USD ($)	May 11, 2021	May 31, 2021	May 31, 2020	Jun. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Research and development expense					$ 915,363	$ 273,038	$ 1,843,397	$ 463,306
IPO [Member]
Number of shares of common stock	3,078,224
Vernalis Development Limited [Member]
Research and development expense				$ 150,000
Development milestone payment			$ 29,900,000
Vernalis Development Limited [Member] \| IPO [Member]
Number of shares of common stock		192,857
Future milestone payments		$ 1,350,000
Vernalis Development Limited [Member] \| Minimum [Member]
Marketing authorization amount			350,000
Sales milestone payments			10,000,000
Cumulative annual net sales amount			500,000,000
Vernalis Development Limited [Member] \| Maximum [Member]
Marketing authorization amount			3,000,000
Sales milestone payments			25,000,000
Cumulative annual net sales amount			$ 1,000,000,000